Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations

Abstract BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverg...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: S. Vasudevan, E. Flashner-Abramson, Heba Alkhatib, Sangita Roy Chowdhury, I. A. Adejumobi, D. Vilenski, S. Stefansky, A. M. Rubinstein, N. Kravchenko-Balasha
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/3fa3ce4bd8c843c780d29b16c0e89e36
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!